

May 17, 2022

National Stock Exchange of India Limited  
Exchange Plaza,  
Plot No. C/1, G Block,  
Bandra Kurla Complex, Bandra (E)  
Mumbai – 400 051

BSE Limited  
Corporate Relationship Department  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai- 400001

**Subject: Press Release for Audited Financial Results (Standalone and Consolidated) for the Quarter and Financial Year ended March 31, 2022**

Dear Sir/Madam,

Please find enclosed herewith the Press Release for the Audited Financial Results (Standalone and Consolidated) for the Quarter and Financial Year ended March 31, 2022.

Thanking You,

Yours Faithfully,

For Dr. Lal PathLabs Limited



**Rajat Kalra**  
Company Secretary and Legal Head



Encl: As above

Classification: Internal

**Dr. Lal PathLabs Limited records revenue of Rs 485.5 Cr in Q4 FY 2021-22**

New Delhi, India, May 17, 2022 – Dr. Lal PathLabs Limited (referred to as the “Company”; NSE: LALPATHLAB, BSE: 539524), a leading diagnostic and related healthcare service provider announces their financial results for the quarter ended March 31, 2022. The results includes Suburban Diagnostics wef 12<sup>th</sup> Nov’21, hence, not strictly comparable with previous year.

**Consolidated Performance Highlights: Q4 FY 2021-22 vs Q4 FY 2020-21**

**Revenue: Rs 485.5 Cr, a growth of 12.7%**  
**Normalised EBITDA at Rs 130.7 Cr with margin at 26.9%**  
**PBT at Rs 83.5 Cr with margin at 17.2%, and**  
**PAT Rs 62.1 Cr with margin at 12.8%**

- Operating Revenue increased by 12.7% in Q4 FY22 to Rs. 485.5 Cr vs Rs 431.0 Cr in Q4 FY21
- Covid and Allied contributed 13.6% to Revenue in Q4 FY22
- Normalised EBITDA (after adjustment for stock based compensation, CSR) for Q4 FY22 is at Rs. 130.7 Cr (margins 26.9%) Vs Rs 129.5 Cr in the same quarter last year
- PBT is at Rs 83.5 Cr in Q4 FY22 (Normalised PBT\* at Rs 94.4 Cr, margins 19.4%) vs Rs 110.8 Cr. in Q4 last year
- PAT is at Rs 62.1 Cr in Q4 FY22 (Normalised PAT\* at Rs 72.9 Cr, margins 15.0%) vs Rs 85.1 Cr. in Q4 last year

**Financial Overview (Consolidated) in Rs Cr**

Particulars	Q4			YTD March		
	FY22	FY21	Gr %	FY22	FY21	Gr %
<b>Revenue</b>	<b>485.5</b>	<b>431.0</b>	<b>12.7%</b>	<b>2087.4</b>	<b>1581.3</b>	<b>32.0%</b>
<i>Non Covid</i>	419.7	374.1	12.2%	1691.3	1257.1	34.5%
<i>Covid &amp; Allied</i>	65.8	56.9	15.7%	396.1	324.2	22.2%
<b>Expenditure</b>	<b>364.5</b>	<b>308.9</b>	<b>18.0%</b>	<b>1526.7</b>	<b>1145.0</b>	<b>33.3%</b>
<b>EBITDA</b>	<b>121.1</b>	<b>122.0</b>	<b>-0.8%</b>	<b>560.7</b>	<b>436.3</b>	<b>28.5%</b>
<i>EBITDA Margins</i>	24.9%	28.3%		26.9%	27.6%	
RSU & CSR cost	9.6	7.5		39.7	26.3	
<b>Normalised EBITDA</b>	<b>130.7</b>	<b>129.5</b>	<b>0.9%</b>	<b>600.4</b>	<b>462.6</b>	<b>29.8%</b>
<i>EBITDA Margins</i>	26.9%	30.1%		28.8%	29.3%	
Net other Income/(Interest)	0.2	9.1		22.4	35.3	
Depreciation Cost	37.8	20.3		108.2	77.2	
<b>PBT</b>	<b>83.5</b>	<b>110.8</b>	<b>-24.6%</b>	<b>474.9</b>	<b>394.4</b>	<b>20.4%</b>
<i>Margins</i>	17.2%	25.7%		22.8%	24.9%	
<b>PAT</b>	<b>62.1</b>	<b>85.1</b>	<b>-27.1%</b>	<b>350.3</b>	<b>296.5</b>	<b>18.1%</b>
<i>Margins</i>	12.8%	19.7%		16.8%	18.7%	
<b>EPS</b>	<b>7.4</b>	<b>10.1</b>	<b>-26.6%</b>	<b>41.7</b>	<b>35.3</b>	<b>18.0%</b>
<b>Normalised PBT*</b>	<b>94.4</b>	<b>110.8</b>	<b>-14.8%</b>	<b>493.8</b>	<b>394.4</b>	<b>25.2%</b>
<i>Margins</i>	19.4%	25.7%		23.7%	24.9%	
<b>Normalised PAT*</b>	<b>72.9</b>	<b>85.1</b>	<b>-14.3%</b>	<b>369.1</b>	<b>296.5</b>	<b>24.5%</b>
<i>Margins</i>	15.0%	19.7%		17.7%	18.7%	

\*Normalised PBT and PAT are excluding notional depreciation on consolidation of Suburban.



## About Dr. Lal PathLabs Limited

---

Dr. Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. Through its' integrated, nationwide network, the company offer patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions.

As on March 31, 2022 the company has 277 clinical laboratories (including National Reference Lab at Delhi, Regional Reference Lab at Kolkata & Bangalore), 4,731 Patient Service Centers (PSCs) and 10,599 Pick-up Points (PUPs). Its' customers include individual patients, hospitals and other healthcare providers and corporate customers.

## Contact Details

---

Ved Prakash Goel  
Group Chief Financial Officer  
*Dr. Lal PathLabs Limited*

+91 124 3016500  
[cfo@lalpathlabs.com](mailto:cfo@lalpathlabs.com)

Rakshit Tewari/Gargi Mukherjee  
*Adfactors PR*

+91 9935551036/+91 9650944756  
[rakshit.tewari@adfactorspr.com](mailto:rakshit.tewari@adfactorspr.com)  
[gargi.mukherjee@adfactorspr.com](mailto:gargi.mukherjee@adfactorspr.com)

For further information on Dr. Lal PathLabs see [www.lalpathlabs.com](http://www.lalpathlabs.com)

## Safe Harbour

---

This release contains statements that contain “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Dr. Lal PathLabs future business developments and economic performance. While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macro-economic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance. Dr. Lal PathLabs undertakes no obligation to publicly revise any forward looking statements to reflect future / likely events or circumstances.